Business
Novavax Announces Leadership Appointment and Updates
- Denny Kim, M.D. appointed Senior Vice President, Chief Safety Officer - Raburn Mallory, M.D. promoted to Senior Vice President, Head of Clinical Development
About this update from Novavax, Inc.
[{"type":"text","content":"- Denny Kim, M.D. appointed Senior Vice President, Chief Safety Officer\n - Raburn Mallory, M.D. promoted to Senior Vice President, Head of Clinical Development\n - Marco Cacciuttolo, Ph.D. promoted to Senior Vice President, Process and Analytical Development\n\n\nGAITHERSBURG, Md., Oct. 4, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment of Denny Kim, M.D., MPH to the newly created role of Senior Vice President, Chief Safety Officer and Head of Global Vaccine Safety. Dr. Kim will report to Filip Dubovsky, M.D., MPH, FAAP, Executive Vice President and Chief Medical Officer. Novavax also announced the promotions of Raburn Mallory, M.D. to Senior Vice President, Head of Clinical Development, and Marco Cacciuttolo, Ph.D. to Senior Vice President, Process and Analytical Development.\nDr. Kim brings nearly two decades of infectious disease, clinical trial and safety experience to Novavax. He joins the company from Johnson & Johnson (J&J), where he was part of the Office of the Chief Medical Officer with oversight for safety strategies and activities across all therapeutic areas, including direct management responsibilities for the safety of the J&J/Janssen COVID-19 vaccine. Previously, he built and led the global Patient Safety and Pharmacovigilance function at Horizon Pharma, developed a new safety function within Takeda's Vaccine Business Unit, and served as Therapeutic Area Safety Head at both Takeda and Astellas. He holds a Doctor of Medicine from University of Chicago Pritzker School of Medicine, a Master of Public Health from Johns Hopkins University Bloomberg School of Public Health and a Bachelor of Arts from Yale University.\n\"We welcome Denny at an exciting time for Novavax as we finalize our regulatory filings and transition into a commercial-stage organization,\" said Dr. Dubovsky. \"His leadership and COVID-19 vaccine experience uniquely equip him to lead a best-in-class safety and pharmacovigilance function at Novavax.\"\nDr. Raburn Mallory has been promoted to Senior Vice President and Head of Clinical Development. In his new role, Dr. Mallory will lead the clinical development organization, provide strategic direction for the life-cycle management of Novavax' ...